Zydus clears USFDA inspection of its new isolator injectable line at Ahmedabad unit

Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for the Pre-Approval Inspection (PAI) conducted at SEZ oncology injectable manufacturing site in SEZ1, Ahmedabad, in relation to the new isolator injectable line. The inspection was conducted from 4th to 13th November, 2025